September has historically been the worst month for the S 500, a phenomenon called the "September effect." The next few weeks may or may not live up (or down) to these low expectations, but investors need not worry about any short-term blip. Whether the market or particular stocks perform well this month is less important than how they will do in the long run.

With that said, let's look at two biotech stocks to buy this month (or any month) that have excellent long-term prospects: Vertex Pharmaceuticals (NASDAQ: VRTX) and Regeneron Pharmaceuticals (NASDAQ: REGN). 

Vertex defied last year's bear market and has outperformed broader indexes over the trailing-12-month period thanks to solid financial results, a strong economic moat, and an exciting pipeline that should yield plenty of new approvals in the next five years. Let's start with the financial results.

Continue reading

Source Fool.com